Rapport Therapeutics’ (NASDAQ:RAPP) Lock-Up Period Will End on December 4th

Rapport Therapeutics’ (NASDAQ:RAPP) lock-up period is set to end on Wednesday, December 4th. Rapport Therapeutics had issued 8,000,000 shares in its IPO on June 7th. The total size of the offering was $136,000,000 based on an initial share price of $17.00. After the end of Rapport Therapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Rapport Therapeutics Stock Performance

NASDAQ RAPP opened at $22.84 on Friday. The business’s 50 day moving average price is $23.12. Rapport Therapeutics has a twelve month low of $16.55 and a twelve month high of $29.74.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Millennium Management LLC acquired a new position in shares of Rapport Therapeutics in the 2nd quarter valued at about $2,716,000. Perceptive Advisors LLC acquired a new position in Rapport Therapeutics during the second quarter worth $17,403,000. ARCH Venture Management LLC acquired a new position in shares of Rapport Therapeutics during the 2nd quarter valued at about $86,730,000. TD Asset Management Inc bought a new position in Rapport Therapeutics in the 2nd quarter worth $2,361,000. Finally, Johnson & Johnson bought a new position in Rapport Therapeutics in the 2nd quarter worth approximately $58,105,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.